Treace Medical Concepts, Inc. TMCI

Company Overview

Treace Medical Concepts, Inc. is a U.S.-based medical technology company focused on the surgical treatment of bunion and related midfoot deformities. The company operates within the orthopedic and podiatric medical device industry and develops procedure-specific solutions intended to improve outcomes for hallux valgus correction. Treace is best known for its proprietary Lapiplasty® 3D Bunion Correction™ system, which is designed to address the three-dimensional nature of bunion deformities through triplanar correction and stabilization of the affected joint. Revenue is primarily generated through the sale of surgical implants, disposable instruments, fixation systems, and procedural kits used by orthopedic surgeons and podiatrists.

The company serves hospitals, ambulatory surgery centers, and physician practices primarily in the United States, with growing international distribution activity. Treace positions itself as a specialized innovator focused on procedural standardization and surgeon education in bunion surgery, differentiating itself from broader orthopedic device manufacturers through a concentrated portfolio and clinically focused commercialization strategy. Founded in 2013 and headquartered in Ponte Vedra, Florida, the company expanded rapidly following commercialization of the Lapiplasty system and completed its initial public offering in 2021.

Business Operations

Treace Medical Concepts organizes its operations around integrated bunion correction technologies and related surgical solutions. Its primary commercial platform is the Lapiplasty® System, supported by complementary offerings including the Adductoplasty® Midfoot Correction System, SpeedPlate™ fixation products, and additional osteotomy and minimally invasive surgical technologies. The company generates revenue through direct sales of implants, surgical instrumentation, disposables, and recurring procedural products used in lower extremity orthopedic procedures. Sales activities are supported by a direct U.S. sales organization and surgeon training programs intended to increase procedural adoption.

Operations are concentrated primarily in the domestic U.S. market, though the company has pursued selective international expansion through distributors and commercial partnerships. Treace controls proprietary procedural systems, implant designs, instrumentation platforms, and intellectual property related to bunion correction and fixation technologies. The company has also invested in surgeon education infrastructure and clinical evidence generation to support adoption and reimbursement positioning. Public filings indicate ongoing collaboration with healthcare providers and surgical training institutions as part of its commercialization strategy.

Strategic Position & Investments

Treace’s strategic direction has centered on expanding procedural adoption of its bunion correction systems, increasing surgeon penetration, and broadening its portfolio across adjacent forefoot and midfoot deformity categories. Growth initiatives have included investment in sales force expansion, physician education programs, clinical research, and new product development intended to support procedural efficiency and minimally invasive approaches. The company has emphasized evidence-based commercialization through published clinical outcomes and surgeon training initiatives.

The company has also invested in extending its intellectual property portfolio and broadening indications for use across lower extremity orthopedic procedures. Strategic efforts have included development of next-generation fixation systems and complementary technologies designed to integrate with the Lapiplasty® platform. Public disclosures identify ongoing investment in research and development capabilities, manufacturing scale, and procedural innovation rather than large-scale acquisition activity. Data regarding any material unconsolidated portfolio investments or significant joint venture holdings is inconclusive based on available public sources.

Geographic Footprint

Treace Medical Concepts is headquartered in Ponte Vedra, Florida, and derives the substantial majority of its revenue from the United States market. The company maintains a nationwide commercial presence through direct sales representatives and clinical support personnel serving hospitals, ambulatory surgery centers, and physician offices. Its surgeon education and training activities are also concentrated within major U.S. orthopedic and podiatric markets.

Outside the United States, Treace has pursued limited but growing international distribution relationships in selected markets across Europe and other regions. International operations remain comparatively smaller relative to domestic activities based on public filings. The company’s operational influence is primarily tied to commercialization of proprietary bunion correction systems and expansion of surgeon adoption rather than large-scale manufacturing or multinational infrastructure.

Leadership & Governance

Treace Medical Concepts was founded by orthopedic device entrepreneur John T. Treace, who has played a central role in shaping the company’s commercialization and procedural innovation strategy. Leadership has consistently emphasized surgeon-focused product development, procedural reproducibility, clinical evidence generation, and specialized market positioning within foot and ankle surgery. Governance oversight is provided through a board structure consistent with publicly traded U.S. medical technology companies and supported by audit, compensation, and nominating committees.

Key executives include:

• John T. Treace – Founder, Chairman, President and Chief Executive Officer
• Mark Hair – Chief Financial Officer
• James T. Treace – Executive Vice President and Chief Commercial Officer
• Christopher L. Gayton – Chief Legal Officer and General Counsel
• Brian K. Straus – Chief Medical Officer

Leadership strategy has focused on expanding procedural adoption of the company’s core technologies, increasing recurring utilization by surgeons, and maintaining specialization in bunion and midfoot deformity correction rather than diversifying broadly across orthopedic categories.